Insider transactions

EDGAR

JUPITER NEUROSCIENCES, INC.

Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.

A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.

Window: transactions dated on or after 2025-11-20.

Open-market purchases (code P)
0 transactions, — shares
Open-market sales (code S)
0 transactions, — shares

Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.

Showing 1–13 of 13

Insider transactions, newest first, as filed on SEC Forms 3, 4 and 5
DateReporting ownerCodeAcquired or disposedSharesPrice per share, as filedValue (derived)Shares owned afterDirect or indirectRule 10b5-1 boxNotesSource
2026-07-31 Filed 2026-08-05Cutler Andrew Jon Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (472,222) — exercise price 0.09
Acquired (A)472,2220—472,222Direct (D) No
F1
  • F1 Represents a grant of 472,222 stock options (each representing the right to purchase one share of Common Stock) under the Issuer's 2025 Equity Incentive Plan. The options were granted in connection with the Reporting Person's appointment to the Board of Directors and the options were granted in lieu of cash compensation otherwise payable as an annual board retainer and committee fees. The options vest with 25 % upfront and the remaining vest in 3 quarterly installments beginning February 1, 2026, subject to the Reporting Person's continued service as a director through each vesting date.
Open filing 0001493152-26-036161 Read from the filing’s XML Dispute this row
2026-06-29 Filed 2026-07-01Philipson Tomas Jan Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option (right to buy) — underlying Common Stock (536,428) — exercise price 0.21
Acquired (A)536,4280—536,428Direct (D) No
F1
  • F1 Represents a grant of 536,428 stock options (each representing the right to purchase one share of Common Stock) under the Issuer's 2025 Equity Incentive Plan. Of this amount, 90,000 options were granted in connection with the Reporting Person's appointment to the Board of Directors and 446,428 options were granted in lieu of cash compensation otherwise payable as an annual board retainer and committee fees. The options vest in 12 equal quarterly installments beginning September 2, 2026, subject to the Reporting Person's continued service as a director through each vesting date.
Open filing 0001493152-26-031539 Read from the filing’s XML Dispute this row
2026-06-02 Filed 2026-06-05Brady Allison W Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option — underlying Common Stock (100,000) — exercise price 0.2783
Acquired (A)100,0000—100,000Direct (D) No
F1
  • F1 The options were granted under the Issuer's 2025 Equity Incentive Plan. The options vest over three years commencing from September 2, 2026 in equal quarterly installments subject to continued service through each vesting date.
Open filing 0001493152-26-027421 Read from the filing’s XML Dispute this row
2026-06-02 Filed 2026-06-04Hemmerly Nicholas H. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option — underlying Common Stock (100,000) — exercise price 0.2783
Acquired (A)100,0000—100,000Direct (D) No
F1
  • F1 The options were granted under the Issuer's 2025 Equity Incentive Plan. The options vest over three years commencing from September 2, 2026 in equal quarterly installments subject to continued service through each vesting date.
Open filing 0001493152-26-027364 Read from the filing’s XML Dispute this row
2026-06-02 Filed 2026-06-04Weis Holger Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option — underlying Common Stock (100,000) — exercise price 0.2783
Acquired (A)100,0000—100,000Direct (D) No
F1
  • F1 The options were granted under the Issuer's 2025 Equity Incentive Plan. The options vest over three years commencing from September 2, 2026 in equal quarterly installments subject to continued service through each vesting date.
Open filing 0001493152-26-027354 Read from the filing’s XML Dispute this row
2026-06-02 Filed 2026-06-04ROSEN CHRISTER Director · Officer: CEO and Chairman
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option — underlying Common Stock (747,783) — exercise price 0.2783
Acquired (A)747,7830—747,783Direct (D) No
F1
  • F1 747,783 options were granted under the Issuer's 2025 Equity Incentive Plan as a discretionary bonus for services rendered during fiscal 2025. The options vest over three years commencing from September 2, 2026 in equal quarterly installments subject to continued employment through each vesting date.
Open filing 0001493152-26-027365 Read from the filing’s XML Dispute this row
2026-06-02 Filed 2026-06-04Elmasri Saleem Officer: Chief Financial Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option — underlying Common Stock (525,565) — exercise price 0.2783
Acquired (A)525,5650—525,565Direct (D) No
F1
  • F1 325,565 options were granted under the Issuer's 2025 Equity Incentive Plan as a discretionary bonus for services rendered during fiscal 2025. 200,000 options were granted under the Issuer's 2025 Equity Incentive Plan as long-term incentive compensation. The options vest over three years commencing from September 2, 2026 in equal quarterly installments subject to continued employment through each vesting date.
Open filing 0001493152-26-027366 Read from the filing’s XML Dispute this row
2026-06-02 Filed 2026-06-04Silva Alison D. Director · Officer: President and COO
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option — underlying Common Stock (1,027,304) — exercise price 0.2783
Acquired (A)1,027,3040—1,027,304Direct (D) No
F1
  • F1 427,304 options were granted under the Issuer's 2025 Equity Incentive Plan as a discretionary bonus for services rendered during fiscal 2025. 600,000 options were granted under the Issuer's 2025 Equity Incentive Plan as long-term incentive compensation. The options vest over three years commencing from September 2, 2026 in equal quarterly installments subject to continued employment through each vesting date.
Open filing 0001493152-26-027362 Read from the filing’s XML Dispute this row
2026-06-02 Filed 2026-06-04Kampf Julie B. Director
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option — underlying Common Stock (100,000) — exercise price 0.2783
Acquired (A)100,0000—100,000Direct (D) No
F1
  • F1 The options were granted under the Issuer's 2025 Equity Incentive Plan. The options vest over three years commencing from September 2, 2026 in equal quarterly installments subject to continued service through each vesting date.
Open filing 0001493152-26-027363 Read from the filing’s XML Dispute this row
2026-06-02 Filed 2026-06-04Rosen Alexander Gustaf Erik Officer: Chief Administrative Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option — underlying Common Stock (341,843) — exercise price 0.2783
Acquired (A)341,8430—341,843Direct (D) No
F1
  • F1 341,843 options were granted under the Issuer's 2025 Equity Incentive Plan as a discretionary bonus for services rendered during fiscal 2025. The options vest over three years commencing from September 2, 2026 in equal quarterly installments subject to continued employment through each vesting date.
Open filing 0001493152-26-027353 Read from the filing’s XML Dispute this row
2026-06-02 Filed 2026-06-04Hayward Marshall A. Director · Officer: Chief Scientific Officer
A

Grant, award or other acquisition pursuant to Rule 16b-3(d)

Derivative security: Stock Option — underlying Common Stock (259,231) — exercise price 0.2783
Acquired (A)259,2310—259,231Direct (D) No
F1
  • F1 259,231 options were granted under the Issuer's 2025 Equity Incentive Plan as a discretionary bonus for services rendered during fiscal 2025. The options vest over three years commencing from September 2, 2026 in equal quarterly installments subject to continued employment through each vesting date.
Open filing 0001493152-26-027361 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-07-13Hayward Marshall A. Director · Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Common Stock
Acquired (A)225,000——2,995,077Direct (D) No
F3
  • F3 The shares underlying this option vested 100% on January 1, 2016 under the Company's 2016 Equity Incentive Plan.
Open filing 0001493152-26-033015 Read from the filing’s XML Dispute this row
2026-03-02 Filed 2026-07-13Hayward Marshall A. Director · Officer: Chief Scientific Officer
M

Exercise or conversion of derivative security exempted pursuant to Rule 16b-3

Derivative security: Stock Option (right to buy) — underlying Common stock (225,000) — exercise price 0.01
Disposed (D)225,0000.00
0

Derived: shares × price per share. Exact value 0.00.

0Direct (D) No
F3
  • F3 The shares underlying this option vested 100% on January 1, 2016 under the Company's 2016 Equity Incentive Plan.
Open filing 0001493152-26-033015 Read from the filing’s XML Dispute this row

Institutional holders (Form 13F)

Quarter ending 2026-09-30: 8,925 filings read, the latest filed 2026-11-19. Prior quarter ending 2026-06-30: 9,176 filings read.

Showing 1–9 of 9

Institutional holders, largest position first, as filed
ManagerShares or principalValue as filedChange from the prior quarterSource
STATE STREET CORP Partly reported under another manager14,500 SH35,380 dollarsNot in the prior quarter’s filings read Open filing 0000093751-26-000747 Filed 2026-11-12 Dispute this row
VESTOR CAPITAL, LLC 14,009 SH3,985 dollarsHigher by 11,816 Prior quarter: 2,193Open filing 0001132699-26-000007 Filed 2026-11-04 Dispute this row
JANE STREET GROUP, LLC Partly reported under another manager13,792 SH33,652 dollarsLower by 519,603 Prior quarter: 533,395Open filing 0001595888-26-000162 Filed 2026-11-12 Dispute this row
UBS Group AG Partly reported under another manager11,703 SH28,555 dollarsNot in the prior quarter’s filings read Open filing 0001610520-26-000121 Filed 2026-11-10 Dispute this row
VANGUARD CAPITAL MANAGEMENT LLC 1,706 SH4,163 dollarsLower by 126,336 Prior quarter: 128,042Open filing 0002100119-26-001711 Filed 2026-11-13 Dispute this row
VANGUARD FIDUCIARY TRUST CO 961 SH2,345 dollarsLower by 83,212 Prior quarter: 84,173Open filing 0000933478-26-000017 Filed 2026-11-13 Dispute this row
Nuveen, LLC Partly reported under another manager457 SH1,179 dollarsNot in the prior quarter’s filings read Open filing 0000930413-26-003284 Filed 2026-11-10 Dispute this row
MidFirst Bank 13 SH32 dollarsLower by 987 Prior quarter: 1,000Open filing 0002077076-26-000006 Filed 2026-11-16 Dispute this row
JPMORGAN CHASE CO Partly reported under another manager1 SH3 dollarsNot in the prior quarter’s filings read Open filing 0000019617-26-000404 Filed 2026-11-12 Dispute this row
Managers in the prior quarter with no filing read for the latest

They may simply not have filed yet: absent from the latest quarter’s filings read is not the same as a position sold.

  • Virtu Financial LLC 231,240 SH
  • GEODE CAPITAL MANAGEMENT, LLC 156,127 SH
  • XTX Topco Ltd 32,770 SH
  • Tower Research Capital LLC (TRC) 28,786 SH
  • NORTHERN TRUST CORP 25,346 SH
  • StoneX Group Inc. 20,602 SH
  • LEVEL FOUR ADVISORY SERVICES, LLC 10,000 SH
  • CITIGROUP INC 546 SH
  • Form 13F covers long positions in Section 13(f) securities only: no short positions and no securities outside that list.
  • Reports for quarters ending before 2013-06-30 were filed as plain text and are not read.
  • A manager that has not yet filed for the latest quarter is absent, not at zero; filings are due up to 45 days after quarter end.
  • A change is the difference between two quarter-end snapshots, not a trade.
  • A position reported under another manager may also appear in that manager’s filing; rows are not added together.
  • Holdings the securities list cannot place with this company, or places ambiguously, are not shown.

Trades by members of Congress

Periodic transaction reports filed by U.S. House members that name this company’s stock. Dates and amounts are as filed.

No House member’s trade in this company is placed in the store. A trade not yet filed or not linked to a company is absent, not zero.

5% holders (Schedule 13D and 13G)

Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.

5% holders, newest event first, as filed
HolderPercent of classShares heldEvent dateFormSource
PharmAla Biotech Holdings Inc. Common Stock, par value $0.0001 per share10.1132,86709/30/2026 Filed 2026-10-26SCHEDULE 13G/AAmendment 1Open filing 0000912282-26-001403 Dispute this row
Orca Capital AG Common Stock, par value $0.0001 per share3.339,945.0008/21/2026 Filed 2026-08-28SCHEDULE 13G/AAmendment 1Open filing 0001493152-26-040641 Dispute this row
Orca Capital AG Common Stock, par value $0.0001 per share8.4102,564.0008/21/2026 Filed 2026-08-28SCHEDULE 13GOpen filing 0001493152-26-040631 Dispute this row
PharmAla Biotech Holdings Inc. Common Stock, par value $0.0001 per share17.3132,86708/20/2026 Filed 2026-09-22SCHEDULE 13GOpen filing 0000912282-26-001297 Dispute this row

Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.

What was read

2,632,462 filings read, dated 2004-06-14 to 2026-11-19: Forms 3, 3/A, 4, 4/A, 5, 5/A.

Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.

Filings read, by filing year
Filing yearFilings read
201549,549
2016222,642
2017222,009
2018223,345
2019216,482
2020226,343
2021249,835
2022231,682
2023229,674
2024234,045
2025235,520
2026263,123

Filings made before the SEC required XML are listed, not extracted.

Back to JUPITER NEUROSCIENCES, INC.